Professional Documents
Culture Documents
Textbook Early Stage Lung Cancer Screening and Management 1St Edition Xiangpeng Zheng Ebook All Chapter PDF
Textbook Early Stage Lung Cancer Screening and Management 1St Edition Xiangpeng Zheng Ebook All Chapter PDF
https://textbookfull.com/product/management-of-early-stage-
breast-cancer-basics-and-controversies-beena-kunheri/
https://textbookfull.com/product/targeted-therapies-in-lung-
cancer-management-strategies-for-nurses-and-practitioners-
marianne-davies/
https://textbookfull.com/product/pet-ct-in-lung-cancer-1st-
edition-archi-agrawal/
https://textbookfull.com/product/cancer-screening-in-
inflammatory-bowel-disease-a-guide-to-risk-management-and-
techniques-joseph-d-feuerstein/
Principles and Practice of Image-Guided Radiation
Therapy of Lung Cancer 1st Edition Jing Cai
https://textbookfull.com/product/principles-and-practice-of-
image-guided-radiation-therapy-of-lung-cancer-1st-edition-jing-
cai/
https://textbookfull.com/product/stage-management-eleventh-
edition-lawrence-stern/
https://textbookfull.com/product/early-phase-cancer-
immunotherapy-1st-edition-sandip-pravin-patel/
https://textbookfull.com/product/spectacular-men-race-gender-and-
nation-on-the-early-american-stage-1st-edition-sarah-e-chinn/
https://textbookfull.com/product/artificial-intelligence-in-
breast-cancer-early-detection-and-diagnosis-khalid-shaikh/
Early-stage
Lung Cancer
Screening and
Management
Xiangpeng Zheng
Ming Li
Guozhen Zhang
Editors
123
Early-stage Lung Cancer
Xiangpeng Zheng • Ming Li • Guozhen Zhang
Editors
Guozhen Zhang
Fudan University Huadong Hospital
Shanghai
China
© Springer Nature Singapore Pte Ltd. and People's Military Medical Press 2018
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of
the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation,
broadcasting, reproduction on microfilms or in any other physical way, and transmission or information
storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology
now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication
does not imply, even in the absence of a specific statement, that such names are exempt from the relevant
protective laws and regulations and therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and information in this book
are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the
editors give a warranty, express or implied, with respect to the material contained herein or for any errors
or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Lung cancer is one of the most common malignant tumors in China. Per cancer
statistics published by the National Cancer Registry Center, over 600,000 new cases
of lung cancer had been registered by 2010, with death resulting in half a million of
them. China is undoubtedly confronting an extremely grim situation with respect to
lung cancer in terms of absolute patient numbers, incidence, and mortality. In con-
trast to the descending trend in more developed Western countries, both the inci-
dence and mortality of lung cancer are still increasing and have not yet peaked in
China, and this growth is partly due to the accelerating industrialization, continuing
urbanization, and changing lifestyles. Current statistics have revealed that more
than half of lung cancers were diagnosed at the advanced or late stage, leading to
poor treatment outcomes and imposing unaffordable economic burdens on both
patients and national healthcare systems. Thus, quality of life and life expectancy
are compromised, and the overall survival of Chinese lung cancer patients lags
behind that of patients in more developed countries.
One of the key issues necessary for improving lung cancer treatment is the need
to promote diagnosis and medical intervention. Early detection, early diagnosis, and
early initiation of medical intervention have been universally accepted as compris-
ing the fundamental principles in the management of lung cancer. However, since
capabilities in diagnosis and medical decision-making vary between clinicians, the
implementation of these principles varies, as well. In this aspect, Fudan University
Huadong Hospital has invested enormous efforts and resources to this cause, mak-
ing remarkable achievements nationally. The following examples are good repre-
sentations of these endeavors.
First, to the best of our knowledge, Huadong Hospital is the first tertiary hospital
nationwide to conduct low-dose CT (LDCT) screening for lung cancer. Thanks to
that initiative, many subcentimeter lung cancers have been detected and surgically
cured, gradually shifting the paradigm of lung cancer screening from traditional
chest radiography to LDCT. The direct benefits of such a paradigm shift include
satisfactory treatment outcomes and life expectancy that is not compromised.
Second, teamwork matters. About a decade ago, to manage the increasingly fre-
quent detection of small pulmonary nodules along with the clinical application of
vii
viii Foreword
he stands on the frontline in the battle against lung cancer, leading the wave of can-
cer research, mentoring young physicians, and educating students.
Written with the intention to share Dr. Zhang’s valuable experience and research
on lung cancer, as well as an interim report of the LN-DTC, this book focuses on the
key pressing issues in lung cancer and its management, with an emphasis on submil-
limeter micronodular pulmonary nodules. The book also discusses advancements
on anatomy, pathology, imaging, and treatment-related lung cancer management.
We strongly believe that this book will be a significant addition to the literature that
exists on lung cancer management in China and worldwide.
We humbly compose this foreword with deep admiration for Dr. Zhang’s lifelong
dedication to lung cancer research and appreciation on the twelfth anniversary of
the center. We wish that every patient suffering from lung cancer could benefit in
some way from Dr. Zhang’s contributions to the field.
At the time when low-dose computed tomography (CT) began to prevail over con-
ventional radiography for lung cancer screening, the detection of subcentimeter pul-
monary nodules began to increase dramatically. In this context, this book discusses
major issues and advancements in the diagnosis and treatment of incidentally
detected, subcentimeter lung cancer (SLC). Dr. Guozhen Zhang, distinguished pro-
fessor in radiology, proposed the “EAST” principle for the management of SLCs:
Early detection, Accurate diagnosis, minimally invasive Surgery, and Teamwork for
precise biopsy. The EAST principle is thoroughly expanded upon throughout the
book. In Part I, experts from pathology and radiology comprehensively review the
state-of-the-art advancements in the screening and evaluation of SLCs, and the
cross-sectional anatomy of the lung and post-processing techniques of CT imaging
are updated. Part II focuses on the imaging features, differential diagnosis, and
radiologic-pathologic correlations of SLCs in the categories of pGGN, mGGN, and
solid nodules, in compliance with the Guidelines on Lung Cancer Screening from
the National Comprehensive Cancer Network (NCCN). Most importantly, the char-
acteristic CT sign for SLC diagnosis and differentiation, the CT angiogram of tumor
angiogenesis (CTA-TA sign), or the “neo-vessel mobilization and intercommunica-
tion” phenomenon—discovered and coined by Dr. Zhang—is extensively discussed.
Part III briefly introduces the therapeutic management strategies for SLCs, includ-
ing surgical and nonsurgical approaches, e.g., stereotactic ablative radiation therapy
(SABR) and radiofrequency ablation (RFA). Finally, to highlight the applicability
of subjects addressed in the previous chapters, authors have meticulously prepared
50 clinical cases of benign and malignant pulmonary nodules with in-depth discus-
sion and experts’ comments for a self-test for readers, with the goal of furthering
understanding of the imaging and the management strategies for SLCs.
xi
Preface
The Twelfth Anniversary of the Zhang Guozhen CT Consultation Center (CCC) and
Lung Nodule Diagnosis and Treatment Center (LN-DTC) at Fudan University
Huadong Hospital.
Lung cancer screening in high-risk populations is a pivotal measure for the early
detection and management of this malignancy. Over the past decade, the screening
approach has gradually evolved from conventional chest radiography to low-dose
CT. With increasing employment of low-dose CT for screening, the number of inci-
dentally detected micronodular lesions spiked. The accurate assessment and proper
management of pulmonary micronodules are critical measures for patients’ longev-
ity and quality of life. Mounting evidence has shown that timely surgical removal of
micronodular lung cancer via video-assisted thoracoscopic surgery (VATS) has dra-
matically improved the prognosis.
With strong support from the hospital administration, the Zhang Guozhen CT
Consultation Center was established in 2005 as China’s first imaging clinic. This
center provided patients with comprehensive imaging consultation, a pattern that
connects radiologists face-to-face with patients, and has won great acclaim for its
improved diagnostic accuracy.
xiii
xiv Preface
Under the leadership of the hospital president, Dr. Yu Zhuowei, the Zhang
Guozhen Center on the Diagnosis and Treatment of Pulmonary Micronodules was
established based on the CT Consultation Center and was joined by experts from the
Departments of Thoracic Surgery and Radiation Oncology in 2013, to confront the
challenge to medical communities from the increasing incidence of pulmonary
micronodular lesions. In the new center, multidisciplinary medical teams offer
patients one-stop medical services from diagnosis to treatment, which is consistent
with international standards of cancer management, with the characteristics of indi-
vidualized treatment to benefit patients to the furthest extent possible.
Based on thousands of micronodular lung cancer cases over the past decade, we
propose an “EAST” principle for the management of SLCs that includes Early
detection of subcentimeter nodules, Accurate diagnosis of lung cancers at stages 0/I,
prompt Surgical removal of SLCs, and Teamwork for the pre-/postoperative local-
ization of nodules for pathological assessment, with the goal of detecting and
eradicating lung cancer at stages 0/I. Obviously, the challenge is massive. However,
considering the astonishing 10-year survival of nearly 100% and the tremendous
savings on social healthcare payments due to unnecessary adjuvant chemotherapy
or radiotherapy, any endeavors to deal with such challenges are worthwhile. We
have established systemic and reliable strategies in the diagnosis and treatment of
SLCs, represented by the CT angiogram of tumor angiogenesis (CTA-TA) and the
CT-guided fine-needle puncturing (CT-FNP) technique. Using these strategies, the
center has achieved diagnostic accuracy in SLCs of above 95%.
During consultations and teaching in the past years, we noticed a lack of consen-
sus in the clinic-radiologic-pathologic relationship, imaging techniques, and the
management strategies for micronodular lung cancer, particularly adenocarcinoma
in situ (AIS). Diagnostic standards and skills vary among physicians, hospitals, and
regions, causing false-positive or false-negative diagnoses that subsequently mis-
takenly guide further medical intervention. This is one of the major reasons for a
poor prognosis. Today, thanks to advancements in imaging techniques, the propor-
tion of AIS in lung cancer has increased to above 30% from less than 5% in the
1980s, changing the profile of lung cancer. Therefore, it is extremely important to
expand the research on diagnosis and treatment of very early-stage lung cancer for
all parties involved in the management of this disease. Unfortunately, there is a lack
of systematic materials such as books, training courses, or symposiums focusing on
imaging assessment and management strategies for micronodular lung cancer.
Hence, we decided to edit this book based on our previous work, emphasizing
practicability.
In Part I, experts from pathology and radiology comprehensively review the
state-of-the-art advancements of SLC in individual research fields, and information
on the cross-sectional anatomy of the lung and post-processing techniques of CT
imaging is updated. Part II focuses on the imaging features, differential diagnosis,
and radiologic-pathologic correlations of SLCs, which are divided into three cate-
gories, namely, pGGN, mGGN, and solid nodules, in compliance with the Guidelines
on Lung Cancer Screening from the National Comprehensive Cancer Network
(NCCN). Most importantly, the characteristic CT sign for SLC diagnosis and dif-
Preface xv
xvii
xviii Contents
Index������������������������������������������������������������������������������������������������������������������ 415
Contributors
xix
xx Contributors
xxiii
xxiv Abbreviations
N. Li • J. Zhang (*)
Department of Pathology, Shanghai Jiaotong University, Shanghai Chest Hospital,
Shanghai, China
M. Li
Department of Radiology, Fudan University Huadong Hospital, Shanghai, China
© Springer Nature Singapore Pte Ltd. and People’s Military Medical Press 2018 3
X. Zheng et al. (eds.), Early-stage Lung Cancer,
https://doi.org/10.1007/978-981-10-7596-4_1
4 N. Li et al.
Thus, it is speculated that AAH could probably be the early event during the process
from adenoma to adenocarcinoma. Subsequently, a large number of molecular biol-
ogy studies, including the mutation of K-ras and EGFR, the polymorphism of K-ras,
the expression of p53, and the lack of alleles, methylation, and overexpression of
telomerase, confirmed the close relationship between AAH and lung adenocarci-
noma from the cellular or genetic levels. In 1999, the WHO histopathologic classi-
fication officially introduced the concept of AAH with the definition of a preinvasive
lesion of lung adenocarcinoma, which was applied in the consecutive 2004 WHO
classification.
The current concept of AIS is modified from previous bronchioloalveolar adeno-
carcinoma (BAC). With regard to BAC, Masayuki Noguchi, a Japanese pathologist,
conducted a pioneering work. In 1995, Noguchi et al. published a study report on
the analysis of resected peripheral lung adenocarcinomas less than 2 cm from 276
cases [1]. By histological examination, small adenocarcinomas were grouped into
six distinctive structural patterns: Noguchi types A, B, C, D, E, and F. These char-
acteristic appearances were well correlated with the macroscopic features of the
tumors and differences in their clinical behavior.
Histologically, type A BACs are well-differentiated localized diseases. Tumors
are solitary, usually larger than 1 cm in greatest dimension with indistinct boundar-
ies. Alveolar architectures remain intact but alveolar lining cells are replaced with
minimal or mild thickening of the alveolar septa. Type A tumors are distinguishable
from AAHs (or adenomas) by increased cellularity and cell atypia. Individual tumor
cells resemble Clara cells, type II pneumocytes, or goblet cells. Fibrotic foci in the
tumors are absent. Type B BACs have foci of alveolar structural collapse on the
basis of type A diseases. Thus, except the fibrotic foci due to alveolar collapse, the
overall microscopic appearance of type B is similar to that of type A, showing a
replacement growth pattern and indistinct boundaries. Unique pleural indentation
due to alveolar collapse is often detected.
The major feature of type C diseases is foci of active fibroblastic proliferation
within localized lesions. Within the lesion, numerous fibroblasts with large nuclei
are seen. And endothelial cells actively proliferate to generate neovasculatures.
However, in the foci of alveolar collapse, active fibroblasts are absent, distinct from
type B. Those tumor cells located in the fibroblastic foci have larger and more atypi-
cal nuclei than those in the peripheral region. In the periphery, tumor cells gradually
replace pre-existing alveolar lining cells. Pleural indentation is a common finding.
In some cases, it is difficult to distinguish type C from type B macroscopically.
Type D BACs are poorly differentiated adenocarcinoma with clear boundaries
between cancer tissues and the noncancerous parenchyma. The tumor shows largely
solid growth, with minor components of papillary and tubular growth, which makes
it somehow resemble large cell carcinoma. Type E diseases, tubular adenocarci-
noma, consist of acinar, tubular, and cribriform architecture, presumptively origi-
nating from or differentiating toward bronchial gland cells. Tumor cells with a
signet ring appearance may be observed. The tumor boundary is always distinct.
Type F diseases are papillary adenocarcinoma with a compressive growth pattern.
Tumors grow in an expansive and destructive pattern, instead of replacing the
1 Advances in the Pathology of Lung Adenocarcinoma 5
a lveolar lining cells as in other types. Thus, they have clear margins and usually are
diagnosed as well-differentiated papillary adenocarcinomas, made up of tall colum-
nar cells of the bronchial surface epithelial type.
The pathological classification has implications on clinical prognosis. The
5-year survival rate for types A and B was approximately l00% in comparison to
74.8% for type C, similar to the prognosis for small-sized pulmonary adenocarci-
noma. Type C is viewed as an advanced carcinoma, evolving from type A or B in
consistency with the concept of a multistep progression of pulmonary adenocarci-
noma. In contrast, types D, E, and F are non-replacement-type adenocarcinomas
with a worse prognosis than replacement-type adenocarcinomas (types A, B, and
C). A stepwise progression has not been observed in these types, which implies a
de novo pathogenesis for them. For those tumors classified as type C, D, E, or F,
pulmonary lobectomy with lymph node dissection is the standard of care. If a tumor
is type A or B, however, extensive lymph node dissection may be omitted. In the
1999 WHO classification system, Noguchi types A and B were designated as bron-
chioloalveolar carcinoma, and the 2004 WHO classification maintains the
designation.
In 2011, IASLC/ATS/ERS proposed a multidisciplinary classification of lung
adenocarcinoma on the basis of WHO classification system. According to the 2011
classification, pulmonary adenocarcinomas were grouped into three categories: pre-
invasive lesion, MIA, and invasive adenocarcinoma. Preinvasive lesions include
AAH and AIS. Invasive adenocarcinoma could have multiple presentations, includ-
ing lepidic, acinar, papillary, micropapillary, and solid with mucin production pre-
dominant. In addition, invasive adenocarcinoma had four variants, invasive
mucinous adenocarcinoma, colloid adenocarcinoma, fetal adenocarcinoma, and
enteric adenocarcinoma. For the first time, AIS and MIA were divided into three
subtypes, non-mucinous, mucinous, and mixed (non-mucinous/mucinous). A com-
parative analysis between Noguchi classification and the 2011 classification indi-
cates that type A is corresponding to classic AIS, type B to AIS with complex
architecture, some of type C to MIA, and invasive adenocarcinoma covers types D,
E, and F. The 2011 multidisciplinary classification system has been widely accepted
in the clinical practice and studies of pulmonary adenocarcinoma.
from multiple organizations, including the International Association for the Study
of Lung Cancer (IASLC), American Thoracic Society (ATS), and European
Respiratory Society (ERS). The 2011 IASLC/ATS/ERS multidisciplinary lung ade-
nocarcinoma classification (hereinafter referred to as “2011 classification”) revised
the conventional histopathologic classification which had been formulated exclu-
sively by pathologists and without the participation of other professionals [2]. The
2011 classification solicited advice and comments from multidisciplinary panel
members, including thoracic medical and surgical oncologists, pulmonologists,
radiologists, molecular biologists, and pathologists as well. The purpose is to pro-
vide an integrated classification system on the basis of comprehensive advancement
of lung adenocarcinoma from every aspect. Moreover, the 2011 classification is
expected to reflect mounting evidence of prognostic and predictive researches and
to guide the clinical management of lung adenocarcinoma. The majority of the 2011
classification was adopted by the 2015 World Health Organization (WHO)
Classification of Tumors of the Lung, Pleura, Thymus and Heart with minor modi-
fications (Table 1.1).
With the extensive adoption of 2011 classification in clinical practice, patholo-
gists are required to update their knowledge to keep abreast of the trend in lung
adenocarcinoma. During this course, there may have issues and uncertainty of
applying the new system to the pathological diagnosis of early lung adenocarci-
noma (including adenocarcinoma in situ and minimally invasive adenocarcinoma),
which would be discussed from four aspects in the following sections.
One of the major updates in the 2011 classification and the 2015 WHO classifica-
tion is the discontinuation of “bronchioloalveolar carcinoma, BAC” and the induc-
tion of “adenocarcinoma in situ.” By definition, the neoplastic cells in AIS lesions
grow along pre-existing alveolar septa (lepidic growth) without stromal, lympho-
vascular, pleural, or alveolar space invasion. As known, most of the invasive adeno-
carcinomas develop from AAH, AIS, and MIA. In this dynamic evolution, especially
in the early steps (AAH, AIS, and MIA), neoplastic cells grow in a lepidic pattern.
In the past, adenocarcinomas with lepidic growth were diagnosed as BAC. With
advancements in lung adenocarcinoma, lepidic growth can be observed in multiple
subgroups with distinct prognosis (for instance, adenocarcinoma with a pure lepidic
pattern, lepidic predominant invasive adenocarcinoma, and other subtypes of pre-
dominant invasive adenocarcinoma comprised of a lepidic pattern). According to
the statistics reported in the 2004 WHO classification, the prevalence of BAC among
lung adenocarcinomas is about 4%, but it could be as high as 22% according to
some literature due to the heterogeneity of diagnostic criteria. The fluctuation in
prevalence causes confusion not only in clinical practices and basic researches but
also in tumor epidemiology. Therefore, in the 2011 classification, the panel recom-
mended discontinuing the use of the term BAC but regrouping subtypes of BAC on
the basis of histopathologic features, clinical presentations, and prognosis using
more specific terms. Accordingly, AIS is introduced to describe localized, small
(≤3 cm) adenocarcinoma with a growth restricted to neoplastic cells along pre-
existing alveolar structures without collateral invasion. Tumors that meet criteria for
AIS have formerly been classified as BAC by the criteria of the 1999 and 2004
WHO classifications and type A and type B adenocarcinoma by the 1995 Noguchi
classification system.
In 2011 classification, AAH and AIS are classified as preinvasive lesions. AAH is a
localized, small, usually 0.5 cm or less (Fig. 1.1a, b) proliferation of mildly to mod-
erately atypical type II pneumocytes and/or Clara cells lining intact alveolar walls
and occasionally respiratory bronchioles. Tumor cells could be rounded, cuboidal,
low columnar, or “peg” cells with round to oval nuclei. Gaps are usually seen
between cells (Fig. 1.1c). Intranuclear inclusions are frequent in neoplastic cells.
These mitoses are extremely rare. There is a continuum of morphologic changes
between AAH and AIS. A spectrum of cellularity and histological atypia occurs in
AAH. The distinction between more cellular and atypical AAH and AIS can be dif-
ficult in histology and impossible in cytology. Radiologically, AAH characteristi-
cally presents as a faint, pure ground-glass nodule (GGN), usually measuring 5 mm
8 N. Li et al.
a b
c d
Fig. 1.1 Atypical adenomatous hyperplasia. (a) AAH appears as a pure GGN (arrowhead) in thin-
sliced CT. (b) In resected specimens, AAH is a localized lesion, usually less than 5 mm in diameter
with poorly defined margin (arrowhead). (c) Mildly widened septa and gaps between neoplastic
cells are frequently seen in AAH lesions. (d) Regression is occasionally observed within AAH due
to fibrotic replacement and collapse of alveolar structures. (e) Enlarged view of the region marked
with a yellow box in D
loss. Some have classified AAH into low- and high-grade subtypes. However, the
grading is not recommended according to the 2011 classification.
The concept of AIS in lung adenocarcinoma was put forward in the 2011 lung
adenocarcinoma classification. By definition, AIS (one of the lesions formerly
known as BAC) is a localized small (≤3 cm, Fig. 1.2c–e) adenocarcinoma with
growth restricted to neoplastic cells along pre-existing alveolar structures (lepidic
growth), lacking stromal, lymphovascular, or pleural invasion. Papillary or micro-
papillary patterns and intra-alveolar tumor cells are absent, no spread through air
spaces. Septal widening with sclerosis/elastosis is common, particularly in non-
mucinous AIS. Radiologically, AIS presents typically as a pure GGN. The pure
GGN of AIS usually appears at thin-section CT as slightly higher attenuation than
the very faint GGN of AAH. However, sometimes it appears as a part-solid nodule
(Fig. 1.2a). AIS can be divided into two subtypes, non-mucinous and mucinous.
Most of the AIS is non-mucinous. Mucinous AIS is extremely uncommon and usu-
ally appears solid radiologically. Histologically, no evidence of invasion is seen in
AIS lesions (Fig. 1.3).
Adenocarcinomas containing lepidic grow pattern are not exclusively found in AIS.
Minimally invasive adenocarcinoma (MIA) is introduced to describe those adenocar-
cinomas with lepidic growth pattern and minimal invasion in the 2011 classification
and 2015 WHO classification. By definition, MIA is a small, solitary adenocarci-
noma (≤3 cm), with a predominantly lepidic pattern and ≤5 mm invasion in greatest
dimension in any one focus. The major difference between AIS and MIA is the exis-
tence of minimal or regional invasive components in the latter, and if the invasion
exceeds 5 mm, invasive adenocarcinoma (IAC), lepidic predominant adenocarci-
noma (LPA) in specific, should be diagnosed instead of MIA. Thus, the existence and
extension of invasive component are of significance for the differentiation of AIS,
MIA, and IAC. To be noted, MIA diagnosis is excluded if the tumor contains necro-
sis; invades lymphatics, blood vessels, and pleura; or spreads through air spaces.
The invasive component to be measured in MIA is defined as follows: (1) histo-
logical subtypes other than a lepidic pattern (i.e., acinar, papillary, micropapillary,
and/or solid) or (2) tumor cells infiltrating myofibroblastic stroma. If there are mul-
tiple foci of invasion or the size of invasion is difficult to measure, recent data sug-
gest that an estimate of invasive size can be made by multiplying the total percentage
of the invasive (nonlepidic) components by the total tumor size.
Similar to AIS, MIA can be divided into mucinous and non-mucinous subtypes.
Most of MIA is non-mucinous, and mucinous MIA is rare. MIA is variable in its
imaging presentation and is not fully described yet, but a provisional description of
the non-mucinous type at thin-section CT is a part-solid nodule consisting of a pre-
dominant ground-glass component and a small central solid component measuring
5 mm or less.
10 N. Li et al.
Fig. 1.2 Adenocarcinoma in situ. (a) The majority of AIS (arrowhead) appear as pure GGNs with
slightly higher attenuation than AAHs. (b) AIS (arrowhead) has higher density than AAH in
resected specimens and is usually less than 2 cm
1 Advances in the Pathology of Lung Adenocarcinoma 11
b c
Fig. 1.3 The initial stage of AIS. (a) The neoplastic cells of AIS grow along pre-existing alveolar
architectures without evident intercellular gaps. (b) Alveolar tension increases due to an intense
alignment of neoplastic cells in highly proliferative AIS. (c) Enlarged view of the region marked
with a yellow box in B
The theoretical basis of the 2011 classification and 2015 WHO classification is
the recognition of the multistep evolution in lung adenocarcinoma. Currently, it
has been widely accepted that the progression of the majority of lung adenocarci-
noma follows a stepwise process starting from AAH to AIS, to MIA, to invasive
adenocarcinoma. Of course, an exception exists. Some adenocarcinomas could be
invasive adenocarcinoma at the very beginning by skipping earlier steps (AAH,
AIS, and MIA). In comparison to those with classical developmental steps, these
tumors tend to be highly aggressive in biological behavior, and lymph node metas-
tasis in the lungs and/or mediastinum may occur at the diagnosis.
Another random document with
no related content on Scribd:
greatly embarrassed to deal with it.[293] Any reply that should
repudiate either the treaty obligation or the principles of American
liberty and self-government was out of the question; any reply that
should affirm either the one or the other was fatal to the system
established by Congress in Louisiana. John Randolph, on whose
shoulders the duty fell, made a report on the subject. “It is only under
the torture,” said he, “that this article of the treaty of Paris can be
made to speak the language ascribed to it by the memorialists;” but
after explaining in his own way what the article did not mean, he
surprised his audience by admitting in effect that the law of the last
session was repugnant to the Constitution, and that the people of
Louisiana had a right to self-government.[294] Senator Giles said in
private that Randolph’s report was “a perfect transcript of Randolph’s
own character; it began by setting the claims of the Louisianians at
defiance, and concluded with a proposal to give them more than they
asked.”[295]
Under these influences the three delegates from the creole
society succeeded in getting, not what they asked, but a general
admission that the people of Louisiana had political rights, which
Congress recognized by an Act, approved March 2, 1805, to the
extent of allowing them to elect a General Assembly of twenty-five
representatives, and of promising them admission into the Union
whenever their free inhabitants should reach the number of sixty
thousand. Considering that the people of Louisiana were supposed
to be entitled to “all the rights, advantages, and immunities of
citizens,” Messieurs Sauvé, Derbigny, and Destréhan thought the
concession too small, and expressed themselves strongly on the
subject. Naturally the British minister, as well as other ill-affected
persons at Washington, listened eagerly to the discontent which
promised to breed hostility to the Union.
“The deputies above mentioned,” wrote Merry to his Government,
[296] “who while they had any hopes of obtaining the redress of their
grievances had carefully avoided giving any umbrage or jealousy to
the Government by visiting or holding any intercourse with the agents
of foreign Powers at this place, when they found that their fate was
decided, although the law had not as yet passed, no longer abstained
from communicating with those agents, nor from expressing very
publicly the great dissatisfaction which the law would occasion among
their constituents,—going even so far as to say that it would not be
tolerated, and that they would be obliged to seek redress from some
other quarter; while they observed that the opportunity they had had of
obtaining a correct knowledge of the state of things in this country,
and of witnessing the proceedings of Congress, afforded them no
confidence in the stability of the Union, and furnished them with such
strong motives to be dissatisfied with the form and mode of
government as to make them regret extremely the connection which
they had been forced into with it. These sentiments they continued to
express till the moment of their departure from hence, which took
place the day after the close of the session.”
Another man watched the attitude of the three delegates with
extreme interest. Aaron Burr, March 4, 1805, ceased to hold the
office of Vice-president. Since the previous August he had awaited
the report of his friend Colonel Williamson, who entered into
conferences with members of the British ministry, hoping to gain their
support for Burr’s plan of creating a Western Confederacy in the
Valley of the Ohio. No sooner was Burr out of office than he went to
Merry with new communications, which Merry hastened to send to
his Government in a despatch marked “Most secret” in triplicate.[297]
“Mr. Burr (with whom I know that the deputies became very
intimate during their residence here) has mentioned to me that the
inhabitants of Louisiana seem determined to render themselves
independent of the United States, and that the execution of their
design is only delayed by the difficulty of obtaining previously an
assurance of protection and assistance from some foreign Power, and
of concerting and connecting their independence with that of the
inhabitants of the western parts of the United States, who must always
have a command over them by the rivers which communicate with the
Mississippi. It is clear that Mr. Burr (although he has not as yet
confided to me the exact nature and extent of his plan) means to
endeavor to be the instrument of effecting such a connection.”
For this purpose Burr asked the aid of the British government,
and defined the nature of the assistance he should need,—a British
squadron at the mouth of the Mississippi, and a loan of half a million
dollars.
“I have only to add that if a strict confidence could be placed in
him, he certainly possesses, perhaps in a much greater degree than
any other individual in this country, all the talents, energy, intrepidity,
and firmness which are required for such an enterprise.”
Pending an answer to this proposal, Burr was to visit New
Orleans and make himself the head of creole disaffection.
Merry was launched into the full tide of conspiracy. At the close of
Jefferson’s first term he saw reason to hope that he might soon
repay with interest the debt of personal and political annoyance
which he owed. While Yrujo was actively engaged in bringing upon
Madison the anger of Spain and France, Merry endeavored to draw
his Government into a system of open and secret reprisals upon the
President.
That the new French minister was little better disposed than
Merry and Yrujo has been already shown; but his causes for ill-will
were of a different and less personal nature. Before Turreau’s arrival
at Washington in November, 1804, Pichon in one of his last
despatches declared that Jefferson had already alienated every
foreign Power whose enmity could be dangerous to the United
States.
“The state of foreign relations offers a perspective which must put
Mr. Jefferson’s character to proof,” Pichon wrote to Talleyrand in
September, 1804.[298] “The United States find themselves
compromised and at odds with France, England, and Spain at the
same time. This state of things is in great part due to the indecision of
the President, and to the policy which leads him to sacrifice everything
for the sake of his popularity.”